UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

 
• By Cathy Kelly
  
House of mirrors
What does UnitedHealthcare's decision on Neulasta and its biosimilars reflect? That depends on where you stand.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet